Foundation Medicine Inc (FMI) Financial Statements (2025 and earlier)
Company Profile
Business Address |
150 SECOND STREET CAMBRIDGE, MA 02141 |
State of Incorp. | DE |
Fiscal Year End | December 31 |
Industry (SIC) | 8071 - Medical Laboratories (benchmarking) |
More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
6/30/2018 MRQ | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | |||
---|---|---|---|---|---|---|---|---|
ASSETS | ||||||||
Current Assets | ||||||||
Cash, cash equivalents, and short-term investments | 71,404 | 143,019 | 207,370 | 72,080 | 124,293 | |||
Cash and cash equivalents | 71,404 | 63,617 | 117,763 | 72,080 | 124,293 | |||
Short-term investments | 79,402 | 89,607 | ||||||
Receivables | 30,126 | 10,213 | 7,765 | 9,894 | 6,262 | |||
Inventory, net of allowances, customer advances and progress billings | 13,171 | 10,438 | 7,992 | 4,809 | 1,763 | |||
Inventory | 13,171 | 10,438 | 7,992 | 4,809 | 1,763 | |||
Other undisclosed current assets | 9,118 | 5,251 | 6,517 | 2,865 | 992 | |||
Total current assets: | 123,819 | 168,921 | 229,644 | 89,648 | 133,310 | |||
Noncurrent Assets | ||||||||
Property, plant and equipment | 41,119 | 41,486 | 41,333 | 21,015 | 22,104 | |||
Long-term investments and receivables | 24,939 | |||||||
Long-term investments | 24,939 | |||||||
Restricted cash and investments | 2,305 | 1,395 | 1,395 | 864 | 1,725 | |||
Other noncurrent assets | 1,760 | 2,233 | 678 | 411 | 129 | |||
Total noncurrent assets: | 45,184 | 45,114 | 68,345 | 22,290 | 23,958 | |||
TOTAL ASSETS: | 169,003 | 214,035 | 297,989 | 111,938 | 157,268 | |||
LIABILITIES AND EQUITY | ||||||||
Liabilities | ||||||||
Current Liabilities | ||||||||
Accounts payable and accrued liabilities | 58,671 | 32,476 | 23,291 | 19,688 | 15,433 | |||
Employee-related liabilities | 5,011 | 3,258 | ||||||
Accounts payable | 21,926 | 11,898 | 10,469 | 7,263 | 7,007 | |||
Accrued liabilities | 36,745 | 20,578 | 12,822 | 7,414 | 5,168 | |||
Debt | 1,499 | |||||||
Deferred revenue and credits | 4,030 | 4,428 | 2,863 | 1,769 | 2,085 | |||
Other undisclosed current liabilities | 3,742 | 3,747 | 3,742 | (5,011) | (3,258) | |||
Total current liabilities: | 66,443 | 40,651 | 29,896 | 16,446 | 15,759 | |||
Noncurrent Liabilities | ||||||||
Liabilities, other than long-term debt | 60,000 | 9,315 | 9,710 | |||||
Deferred revenue and credits | 9,315 | 9,710 | ||||||
Due to related parties | 60,000 | |||||||
Total noncurrent liabilities: | 60,000 | 9,315 | 9,710 | |||||
Total liabilities: | 126,443 | 40,651 | 29,896 | 25,761 | 25,469 | |||
Equity | ||||||||
Equity, attributable to parent | 31,668 | 164,846 | 257,689 | 86,169 | 131,711 | |||
Common stock | 4 | 4 | 3 | 3 | 3 | |||
Additional paid in capital | 537,904 | 509,664 | 489,480 | 228,151 | 221,471 | |||
Accumulated other comprehensive income (loss) | 109 | (14) | (178) | |||||
Accumulated deficit | (506,349) | (344,808) | (231,616) | (141,985) | (89,763) | |||
Total equity: | 31,668 | 164,846 | 257,689 | 86,169 | 131,711 | |||
Other undisclosed liabilities and equity | 10,892 | 8,538 | 10,404 | 8 | 88 | |||
TOTAL LIABILITIES AND EQUITY: | 169,003 | 214,035 | 297,989 | 111,938 | 157,268 |
Income Statement (P&L) ($ in thousands)
6/30/2018 TTM | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | ||
---|---|---|---|---|---|---|---|
Revenues | 152,903 | 116,865 | 93,203 | 61,079 | 28,990 | ||
Revenue, net | 116,865 | 93,203 | 858 | 854 | |||
Cost of revenue | (67,080) | (52,978) | (36,695) | (27,434) | (11,659) | ||
Gross profit: | 85,823 | 63,887 | 56,508 | 33,645 | 17,331 | ||
Operating expenses | (246,766) | (173,933) | (143,527) | (95,123) | (64,537) | ||
Other undisclosed operating income (loss) | (3,770) | (2,736) | 8,195 | 5,445 | |||
Operating loss: | (160,943) | (113,816) | (89,755) | (53,283) | (41,761) | ||
Nonoperating income (expense) | 204 | 624 | 124 | 1,061 | (1,183) | ||
Other nonoperating income (expense) | 204 | 1,103 | (948) | ||||
Interest and debt expense | (283) | ||||||
Loss from continuing operations: | (161,022) | (113,192) | (89,631) | (52,222) | (42,944) | ||
Loss before gain (loss) on sale of properties: | (161,022) | (113,192) | (89,631) | (52,222) | (42,944) | ||
Net loss: | (161,022) | (113,192) | (89,631) | (52,222) | (42,944) | ||
Other undisclosed net loss attributable to parent | (444) | ||||||
Net loss attributable to parent: | (161,466) | (113,192) | (89,631) | (52,222) | (42,944) | ||
Preferred stock dividends and other adjustments | (139) | ||||||
Net loss available to common stockholders, diluted: | (161,466) | (113,192) | (89,631) | (52,222) | (43,083) |
Comprehensive Income ($ in thousands)
6/30/2018 TTM | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | ||
---|---|---|---|---|---|---|---|
Net loss: | (161,022) | (113,192) | (89,631) | (52,222) | (42,944) | ||
Other comprehensive income (loss) | 123 | 164 | (178) | ||||
Comprehensive loss: | (160,899) | (113,028) | (89,809) | (52,222) | (42,944) | ||
Other undisclosed comprehensive loss, net of tax, attributable to parent | (444) | ||||||
Comprehensive loss, net of tax, attributable to parent: | (161,343) | (113,028) | (89,809) | (52,222) | (42,944) |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.